www.xinhuanet.com
XINHUA online
CHINA VIEW
VIEW CHINA
 Breaking News China, US to hold 2nd strategic dialogue in Washington    FLASH: CANADA'S PARLIAMENT PASSES NON-CONFIDENCE MOTION MONDAY,    Urgent: Blast heard in West Bank city Hebron: Witnesses    Half of offshore sea water polluted    Trial of Saddam postponed to Dec. 5    DPRK demands US compensation for stopping LWRs construction    
Home  
China  
World  
Business  
Technology  
Opinion  
Culture/Edu  
Sports  
Entertainment  
Life/Health  
Travel  
Weather  
RSS  
  About China
  Map
  History
  Constitution
  CPC & Other Parties
  State Organs
  Local Leadership
  White Papers
  Statistics
  Major Projects
  English Websites
  BizChina
- Conferences & Exhibitions
- Investment
- Bidding
- Enterprises
- Policy update
- Technological & Economic Development Zones
Online marketplace of Manufacturers & Wholesalers
   News Photos Voice People BizChina Feature About us   
Canadian company to produce H5N1 flu vaccine
www.chinaview.cn 2005-11-29 16:30:28

    OTTAWA, Nov. 28 (Xinhuanet) -- The Canadian government and the country's flu vaccine manufacturer ID Biomedical have signed a deal that will see the company produce a prototype H5N1 flu vaccine for clinical testing.

    In a statement released Monday, Health Minister Ujjal Dosanjh called the contract an important component of the country's pandemic readiness.

    Under the contract, the Canadian government will pay ID Biomedical 21.2 million Canadian dollars (18 million US dollars) for a currently unspecified number of doses of H5N1 vaccine.

    But the prototype vaccine will not be tested until late 2006. And the process of testing and licensing a prototype H5N1 vaccine will take another year on top of that, Dr. Theresa Tam of the Public Health Agency of Canada said Monday.

    Under the deal, if a pandemic vaccine is rushed to market without undergoing the full testing and licensing process, the government will have to compensate the manufacturer for any claims that might arise if there are adverse reactions to the vaccine. Enditem

  Related Story
Copyright ©2003 Xinhua News Agency. All rights reserved.
Reproduction in whole or in part without permission is prohibited.